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Breast cancera b s t r a c t
Drug delivery using thermosensitive liposomes (TSL) has signiﬁcant potential for tumor drug targeting
and can be combined with local hyperthermia to trigger drug release. Although TSL-mediated drug deliv-
ery can be effective by itself, we developed doxorubicin (DOX)-containing CO2 bubble-generating TSL
(TSL-C) that were found to enhance the antitumor effects of DOX owing to the synergism between burst
release of drug and hyperthermia-induced CO2 generation. An ultrasound imaging system was used to
monitor hyperthermia-induced CO2 generation in TSL-C and the results revealed that
hyperthermia-induced CO2 generation in TSL-C led to increased DOX release compared to that observed
for non-CO2-generating TSL. Moreover, TSL-C signiﬁcantly inhibited the tumor growth in MDA-MB-231
tumor-bearing mice compared to TSL (p < 0.004). Taken together, we demonstrated that the TSL-C plat-
form increased the therapeutic efﬁcacy of cancer chemotherapy and showed the applicability of this
approach to increase drug release within the tumor microenvironment. As a novel and highly effective
drug delivery platform, TSL-C has great potential for use in a broad range of applications for the treatment
of various human diseases.
Statement of Signiﬁcance
We have developed a novel method for drug release from liposomes by gas (CO2) generation in tumor
microenvironment. In addition, we demonstrate therapeutic efﬁcacy in breast carcinoma.
CO2-generated liposomal doxorubicin is a novel and highly attractive delivery system for anticancer drug
with the potential for broad applications in human disease.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction light-sensitive liposomes [10,11], for increased drug release atLiposome-based anticancer drug delivery systems have great
potential for cancer chemotherapies [1,2]. Although liposomes pro-
vide a promising chemotherapeutic strategy, their use in clinical
trials for controlled drug release has been limited. To overcome
the limitations associated with the use of liposomes, surface mod-
iﬁcation by polymers [3,4] and external stimulation-triggered drug
release strategies [5] have been employed to develop advanced
liposomal formulations, such as pH- [6,7], ultrasound- [8,9], andthe target site. Although advanced liposomal systems have been
developed to increase drug release within tumor tissue, the factors
determining the optimum formulation and control of drug release
for effective chemotherapy are not well understood. These issues
have increased the need for novel and improved liposomal systems
to overcome the existing therapeutic limitations.
In particular, thermosensitive liposomes (TSL) have attracted
considerable attention owing to their ability to enhance drug
release at the target site [12,13]. Effective drug release from TSL
in tumor tissue increases the therapeutic efﬁcacy. To increase drug
release from liposomes, we encapsulated both ammonium bicar-
bonate (NH4HCO3) and doxorubicin (DOX) into TSL to generate
CO2 bubbles in response to external hyperthermia [14]. NH4HCO3
is widely used as a CO2 raising agent in the food industry for the
generation of gas bubbles in baked goods, and it can quickly
Fig. 1. Schematic illustration of hyperthermia-induced DOX release from CO2-generating liposomal platform.
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[15,16]. Thus, we postulated that external hyperthermia-induced
gas generation in liposomes could promote drug release by
increasing liposomal membrane destabilization (Fig. 1) [17].
These ﬁndings motivated us to determine whether CO2 bubble
generation in liposomes could promote drug release, leading to
an increased therapeutic efﬁcacy.
Here, we present a novel liposomal DOX platform as a cancer
chemotherapeutic agent designed to increase drug release at the
tumor site by CO2 bubble generation. Furthermore, the therapeutic
efﬁcacy of DOX released from CO2-generating TSL (TSL-C) was
evaluated in the presence or absence of hyperthermia. This study
aimed to provide a signiﬁcant conceptual advance in the under-
standing of liposomal delivery systems for cancer chemotherapy.
2. Materials and methods
2.1. Materials
Dipalmitoylphosphatidyl-choline (DPPC), monostearoylpho
sphatidylcholine (MSPC), and 1,2-distearoyl-sn-glycero-3-phospho
ethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-
mPEG-2000) were purchased from Avanti Polar Lipids Inc.
(Alabaster, AL, USA). Doxorubicin hydrochloride (DOX), citric acid,
4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HPES),
Sephadex G-50, and ammonium bicarbonate (NH4HCO3) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine
serum (FBS), penicillin–streptomycin, and Dulbecco’s modiﬁed
Eagle’s medium (DMEM) were purchased from Gibco BRL/Life
Technologies (New York, NY, USA). All other materials were of
analytical grade and used without further puriﬁcation.
2.2. Preparation of TSL or TSL-C
TSL were prepared by thin-lipid ﬁlm hydration and the sequen-
tial extrusion method [18,19]. The encapsulation of DOX in the
aqueous core of the liposomes was achieved by the remote loading
method using an ammonium sulfate transmembrane gradient. The
lipid compositions and molar ratios for TSL preparation were
DPPC:MSPC:DSPE-mPEG-2000 = 21.6:2.6:1.0. These lipids were
dissolved in 3 ml of chloroform to give a total lipid concentration
of 25.2 mM and dried to a thin ﬁlm using a rotary evaporator under
a vacuum. The ﬁlm was hydrated with 3 ml of 300 mM ammonium
sulfate solution and the resulting liposome suspension was
extruded sequentially 5 times through polycarbonate membrane
ﬁlters (Whatman, Piscataway, NJ, USA) with a pore size of 200
and 100 nm using a high-pressure extruder (Northern Lipids Inc.,
Burnaby, Canada). Free ammonium sulfate was removed by dialy-
sis in distilled water for 48 h at 4 C using a cellulose dialysis tube(MWCO, 12,000–14,000; Viskase Co., Darien, IL, USA). DOX solution
(2 mg/ml) was added to the liposomal suspension (1:1 v/v) and
incubated for 2 h at 25 C. The mixture was then dialyzed for
48 h at 4 C to remove the free DOX.
The CO2-generating TSL-C were also prepared using the
thin-lipid ﬁlm hydration method with minor modiﬁcations of the
TSL preparation. The experimental procedure for the preparation
of TSL-C was similar to that described above. For TSL-C, the dried
lipid ﬁlm was hydrated with 3 ml of 300 mM citric acid buffer solu-
tion (pH 4). DOX solution (2 mg/ml) containing 253 mM of
NH4HCO3 was added to the liposomal solution (1:1 v/v) and incu-
bated for 2 h at 25 C. The mixture was dialyzed for 48 h at 4 C to
remove the free DOX and NH4HCO3. The TSL and TSL-C were stored
at 4 C until use.
The particle size and zeta potential of liposomes were measured
by laser light scattering using a particle size analyzer (ELS-8000,
Outskate, Japan). The loading efﬁciency of DOX into liposomes was
measured by UV–vis spectrophotometry (UV-mini, Shimadzu,
Japan) at wavelength of 490 nm after dissolution of the liposomes
in a chloroform–methanol mixture (8:2, v/v) [19]. In addition, mor-
phologies of TLS-C after bothDOXandNH4HCO3 encapsulationwere
monitored by cryogenic transmission electron microscopy
(cryo-TEM, Tecnai G2 Spirit, FEI Company, Hillsboro, OR, USA).
2.3. Intracellular uptake of liposomes into tumor cells
The breast cancer cell line, MDA-MB-231, was maintained and
propagated in DMEM supplemented with 10% fetal bovine serum
and 0.1% gentamicin sulfate (Gemini Bioproducts, Calabasas, CA).
All in vitro and in vivo experiments were conducted when cells
were 70–80% conﬂuent. The intracellular uptake of TSL or TSL-C
was observed using ﬂow cytometry (FACScan, Becton Dickinson)
with CELLQuest software (Becton Dickinson Immunocytometry
System, Mountain View, CA). The MDA-MB-231 cells were plated
in a 6-well plate at a density of 2  105 cells per well and cultured
in DMEM at 37 C. This culture mediumwas replaced with 2 ml per
well of culture medium containing liposomal solutions. The cells
were incubated with liposomes for 1 h at 37 C in a 5% CO2 incuba-
tor. After incubation, the cells were washed 3 times with
phosphate-buffered saline (PBS). The intracellular uptake of lipo-
somes in MDA-MB-231 cells was monitored by ﬂow cytometry,
and the morphologies of tumor cells containing TSL-C were
observed by confocal microscopy (Carl Zeiss, LSM 710, Germany).
2.4. Observation of CO2 generation in TSL-C by ultrasound imaging
The generation of CO2 in TSL-C was monitored using an ultra-
sound imaging system with a 7 MHz transducer (TELEMED,
Lithuania). The TSL and TSL-C were placed in round bottomed
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eration was automatically displayed by B-mode anatomic images.
2.5. Drug release from TSL-C
Temperature-sensitive drug release from liposomes was mea-
sured as a function of temperature and incubation time. The lipo-
some suspensions were diluted with PBS (pH 7.4) at a ratio of
1:4 (v/v). The release of DOX from liposomes was measured using
a UV–vis spectrophotometer (UV-mini) at a wavelength of 490 nm.
The percentage of DOX released from the liposomes was calculated
according to the formula [8]:
Drug release ð%Þ ¼ ðFt  F0Þ=ðFmax  F0Þ  100
where Ft was the DOX intensity of the liposome, F0 was the initial
background DOX intensity of the liposome, and Fmax was the inten-
sity of DOX in the liposomes after the dissolution of DOX-loaded
liposomes in the organic solvent mixture consisting of chloroform
and methanol (4:1 v/v). The drug-release test was performed using
3 independent samples of each liposomal formulation.
2.6. Cytotoxicity of TSL-C
The cytotoxicity of the TSL and TSL-C with or without hyper-
thermia was determined by MTT assay [20]. The MDA-MB-231
cells were seeded into 96-well plates at a density of 1  103 cells
per well and cultured at 37 C in 5% CO2 for 2 h in DMEM contain-
ing liposomes. After incubation, the plates were heated to 42 C for
2 min to trigger CO2 generation in TSL-C. Thereafter, the plates
were washed with PBS, the medium was replaced, and the cells
were incubated for 48 h. The absorbance was measured at
590 nm using a microplate reader (EL808, Bio-Tek, Ins., USA).
2.7. Cell death assay for TSL-C
The relative percentage of necrotic and apoptotic cells was
assessed using the Annexin V-FITC apoptosis Detection Kit-1 (BD
Pharmingen, San Diego, CA) according to the manufacturer’s proto-
col. Brieﬂy, control, TSL, and TSL-C were incubated with
MDA-MB-231 cells for 30 min at room temperature to induce
intracellular delivery of liposomes. After that, the plates were
heated to 42 C for 10 min to generate CO2 within TSL-C.
Thereafter, the cells were incubated for 24 h. After incubation,
the cells were washed twice in PBS, and the pellet was resus-
pended in annexin V binding buffer at a concentration of 106 -
cells/ml. Annexin-propidium iodide (PE) and 7-AAD
(7-amino-actinomycin D) were added (5 ll of each per 105 cells).
Samples were mixed gently and incubated for 15 min at room tem-
perature in the dark before ﬂow cytometry analysis [21].
2.8. Antitumor efﬁcacy
Female athymic nude mice (NCr-nu) were purchased from
Orient Co. (Seoul, South Korea). All mouse studies were approved
by the Konkuk University Institutional Animal Care and Use
Committee (Ref. No. KU14009). The mice used for in vivo experi-
ments were 5–6 weeks old. To produce tumors, MDA-MD-231
(5  105 cells per 0.05 ml HBSS) cells were injected into the subcu-
taneous (s.c.) of mice. Mice (n = 6 per group) were monitored daily
for adverse effects of therapy and were sacriﬁced when any of the
mice seemed moribund.
To assess tumor growth, treatment began 1 week after s.c. injec-
tion of MDA-MB-231 cells into mice. TSL-C was given once weekly
at a dose of 5 mg DOX/kg body weight through intravenous (i.v.)
injection. Four hours after i.v. injection of TSL-C, a near infrared
(NIR) laser as a heat source for hyperthermia was irradiated at1.75W/cm2 for 3 min. Treatment continued until mice became
moribund (typically 3–4 weeks). Mouse weight, tumor volume,
and tumor weight were recorded. The individuals who performed
the necropsies, tumor collections, and tissue processing were
blinded to the treatment group assignments. Tissue specimens
were ﬁxed with formalin [22].
2.9. Immunohistochemical staining
Immunohistochemical (IHC) analysis was performed on tumor
tissue from mice treated with i.v. injection of TSL-C. Procedures
for IHC analysis of cell proliferation (Ki67) and cell apoptosis (cas-
pase 3 antibody) were performed as described previously [22]. All
of these analyses were recorded in 4 random ﬁelds for each slide.
The quantiﬁcation of apoptotic cells was calculated by the number
of apoptotic cells in 4 random ﬁelds. All staining was quantiﬁed by
2 investigators in a blinded fashion.
2.10. Statistical analysis
Differences in continuous variables were analyzed by Student’s
t-test for comparing two groups and ANOVA was performed to
compare differences between multiple groups. For values that
were not normally distributed, the Mann–Whitney rank sum test
was used. The statistical package for the Social Sciences (SPSS,
Inc.) was used for all statistical analyses. A p value of <0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Characteristics of liposomes
We ﬁrst conﬁrmed the physical properties of the liposomes
(Fig. 2). The mean particle size of TSL and TSL-C were
100.63 ± 3.69 nm and 103.2 ± 5.91 nm, respectively, and the sur-
face charge was 10 mV (Fig. 2A and B). In addition, loading efﬁ-
ciency of DOX into TSL was over 94.76%, and the concentration of
DOX was 880.50 lg/ml, while the loading efﬁciency of TSL-C was
81.03% and the concentration was 811.78 lg/ml (Fig. 2C and D).
The loading efﬁciency of DOX into liposomes was dependent on
the sulfate or citrate gradient [23]. The loading efﬁciency of DOX
into TSL using an ammonium salt gradient was higher than that
of TSL-C when a sodium salt gradient was used. Although the load-
ing efﬁciency of TSL was higher, there were no signiﬁcant differ-
ences between the particle size and surface charge of TSL and
TSL-C, demonstrating that NH4HCO3 encapsulation did not affect
the physicochemical properties of the liposomes.
3.2. Intracellular delivery of TSL or TSL-C in MDA-MB-231 cells
We next assessed the intracellular uptake of liposomes by ﬂow
cytometry and confocal microscopy (Fig. 3). Flow cytometry anal-
ysis indicated that both TSL and TSL-C exhibited highly efﬁcient
and dose-dependent intracellular delivery, as compared to the con-
trol (Fig. 3A and B). In addition, confocal microscopy analysis
showed that TSL-C uptake by tumor cells was consistent with the
ﬂow cytometry data (Fig. 3C).
3.3. CO2-generation and release of DOX from TSL-C
Prior to testing DOX release from liposomes, we monitored
hyperthermia-induced CO2 generation in TSL-C using an ultra-
sound imaging system. While TSL showed no bubble generation,
TSL-C showed CO2 bubble generation at 42 C (Fig. 4A). We next
observed the morphologies of TSL-C before and after hyperthermia
Fig. 2. Physical properties of TSL and TSL-C. (A) Size and (B) zeta potential of liposomes were measured by light scattering with a particle size analyzer. (C) Loading efﬁciency
and (D) concentration of DOX into liposomes were determined by ﬂuorescence spectrophotometry. The data are presented as the mean ± S.D. (n = 3).
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brane destabilization (Fig. 4B). Notably, we observed a black bar
in the center of TSL-C, which clearly indicated DOX encapsulation
into liposomes. However, after hyperthermia, the liposomal mem-
brane destabilized and the size of TSL-C decreased, possibly trig-
gering a release of DOX from the liposomes. This data
demonstrated that CO2 generation by hyperthermia in TSL-C pro-
moted DOX release and membrane destabilization.
The release of DOX from TSL and TSL-C was measured at var-
ious temperatures and times (Fig. 4C and D). At normal body
temperature of 37 C, TSL and TSL-C showed a limited increase
in DOX release, whereas drug release from TSL-C greatlyFig. 3. Intracellular uptake of liposomes. (A and B) Flow cytometric assessment of the in
TSL-C. (C) The intracellular uptake of liposomes in tumor cells was observed by confocaincreased in the hyperthermia region (40–42 C) compared to
TSL (Fig. 4C), indicating that TSL-C was safe in circulation after
injection at body temperature. Moreover, this data also clearly
indicated that CO2 generation in TSL-C promoted DOX release
in hyperthermia conditions. In addition, drug release was mea-
sured at the same incubation in the presence or absence of
hyperthermia (Fig. 4D). Although TSL with hyperthermia resulted
in an increased drug release (60%) within 4 min at 42 C, TSL-C
with hyperthermia showed a much higher increase in drug
release (80%) within 1 min at 42 C, indicating that
hyperthermia-induced CO2 generation within liposomes signiﬁ-
cantly promoted DOX release.tracellular delivery of liposomes in MDA-MB-231 tumor cells incubated with TSL or
l microscopy. Blue: nuclei, Red: DOX, Scale bar: 20 lm.
Fig. 5. Cell death assays. (A and B) Cytotoxicity of TSL and TSL-C containing DOX towards MDA-MB-231 cells with or without hyperthermia (42 C). [H] indicates
hyperthermia treatment at 42 C. (C and D) Cell death assay of MDA-MB-231 cells exposed to TSL or TSL-C. The relative percentage of necrotic and apoptotic cells was
assessed by 7-AAD and annexin V double staining. Afterwards, necrosis and apoptosis were determined by ﬂow cytometry. The data are presented as the mean ± S.D. *p < 0.05.
Fig. 4. Release of DOX from liposomes. (A) The generation of CO2 bubbles in TSL-C was monitored using an ultrasound imaging system with a 7 MHz transducer. (B)
Morphologies of TSL-C encapsulated with DOX and NH4HCO3 before and after hyperthermia were monitored by cryogenic transmission electron microscopy. Scale bar:
100 nm. (C) Release of DOX from liposomes at various temperatures and (D) times. [H] indicates that the liposomes were exposed to hyperthermia at 42 C. The data are
presented as the mean ± S.D. (n = 3).
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To conﬁrm whether cytotoxicity increased following
CO2-mediated DOX release from TSL-C, we determined thein vitro cytotoxicity and apoptosis induced by TSL and TSL-C with
or without hyperthermia by MTT assay and ﬂow cytometry analy-
sis (Fig. 5). The TSL-C with hyperthermia was more cytotoxic
towards MDA-MB-231 cells than either TSL or TSL-C without
Fig. 6. Antitumor effect of TSL-C in MDA-MB-231 tumor bearing mice. (A) Tumor growth and (B) tumor weight were monitored. Treatment was started 1 week after
subcutaneous injection of MDA-MB-231 cells (5  105) into mice (n = 6). TSL-C was given by i.v. injection once per week at a dose of 5 mg/kg body weight. A NIR (near
infrared) laser was used as a local heat source. Four hours after TSL-C injection, the tumor was exposed to NIR at 1.75 W/cm2 (42 C) for 3 min. Treatment was continued until
the mice in any group became moribund. Error bars represent the standard error of the mean s.e.m. *p < 0.004. (C) Immunohistochemical analyses of cell proliferation (Ki67)
and caspase 3 were performed on tumor tissues following treatment with TSL-C with or without hyperthermia. All of these analyses were recorded in 4 random ﬁelds for each
slide. Error bars represent s.e.m. *p < 0.05. Bar: 50 lm.
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TSL-C with hyperthermia clearly indicated that their drug release
increased owing to CO2 generation.
We next assayed necrosis and apoptosis analysis using ﬂow
cytometry (Fig. 5C and D). Cell necrosis increased signiﬁcantly in
the presence of TSL-C compared to TSL at 42 C (*p < 0.01,
Fig. 5C and D). CO2 bubble generation in liposomes ampliﬁed the
cavitation effect [15]. This cavitation effect on lysosomes can
mechanically disrupt the cell membranes, resulting in increased
necrosis [15]. In addition, apoptosis also increased in tumor cells
treated with TSL-C owing to burst release of DOX from liposomes.
Overall, cell death signiﬁcantly increased in the presence of TSL-C
compared to TSL (Fig. 5D).
3.5. Therapeutic efﬁcacy of TSL-C
To determine the effectiveness of potential therapeutic efﬁcacy
of TSL-C, we utilized breast carcinoma MDA-MB-231 cells, which
play a signiﬁcant role in cell invasion, leading to increased metas-
tasis of cancer cells [24]. In addition, breast cancer treatment using
a combination therapy involving external hyperthermia treatment
is promising. Seven days following s.c. injection of tumor cells into
the mice, the animals were randomly allocated to the following
groups (n = 6 mice/group): (1) control without NIR, (2) control with
NIR, (3) TSL-C without NIR, and (4) TSL-C with NIR. All mice were
sacriﬁced when animals in any group appeared moribund. TSL-Cwithout NIR resulted in signiﬁcant inhibition of tumor growth
compared to the control without NIR (36% reduction; p < 0.004).
Notably, the combination of TSL-C with NIR showed the greatest
inhibition of tumor growth compared to the control without NIR
(72% reduction, p < 0.002) and TSL-C without NIR (57% reduction,
p < 0.028; Fig. 6A and B). There were no differences in total body
weight, feeding habits, or behavior between the groups, suggesting
that there were no overt toxicities related to therapy.
To determine the potential mechanisms underlying the efﬁcacy
of TSL-C with NIR therapy in tumor tissues, we examined the
tumors for markers of cell proliferation (Ki67) and apoptosis (cas-
pase 3). TSL-C with NIR signiﬁcantly inhibited cell proliferation
(p < 0.003 vs control without NIR; p < 0.03 vs TSL-C without NIR)
and increased apoptosis (p < 0.001 vs control without NIR;
p < 0.04 vs TSL-C without NIR) (Fig. 6C).4. Discussion
We demonstrate here that a novel liposomal CO2-generating
DOX delivery platform combined with hyperthermia leads to
potent anti-tumor efﬁcacy in breast carcinoma. This approach
has broad utility for enhancing the therapeutic effects on tumor
cells. Hyperthermia-induced CO2 generation within liposomes
resulted in effective drug release and could be applied to multiple
cancer models achieve high therapeutic efﬁcacy.
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with the characteristics of drug release from liposomes.
Conventional TSL are capable of temperature-sensitive drug
release at the target site. Although TSL formulations are capable
for controlled drug release, liposomal systems still need to increase
therapeutic efﬁcacy for sufﬁcient drug release at the tumor site to
increase therapeutic efﬁcacy [12]. Therefore, to increase drug
release from liposomes, stimuli-responsive strategies have been
developed [5]. Among them, CO2 generating liposomes were devel-
oped for drug burst release from liposomes in response to hyper-
thermia or ultrasound irradiation [14,15]. The CO2 generating
liposomal platform has been applied to the treatment of diverse
diseases such as cancer, demonstrating the system’s therapeutic
efﬁcacy [1,17]. Here, we developed an advanced TSL-C system by
encapsulating both ammonium bicarbonate (NH4HCO3) and DOX
into the liposomes, facilitating drug release by CO2 generation
under hyperthermic conditions. This CO2 generating liposomal
platformmay be attractive for many biomedical applications when
combined with local hyperthermia at the target site, including
administration of treatment agents for diseases.
In summary, the TSL-C system has demonstrated great potential
for providing increased drug release at tumor sites in cancer
chemotherapy and will be useful as a drug delivery system for
treating many other diseases. In addition, the use of the TSL-C
delivery system can be useful in a range of
hyperthermia-mediated therapies, and additional approaches can
be developed to expand their usage. Overall, this
hyperthermia-triggered drug release using CO2 generation has
demonstrated great potential for use as a systemic delivery plat-
form for the treatment of a variety of human diseases and could
be adapted to enhance other therapeutic approaches requiring
speciﬁc therapeutic capabilities.
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Appendix A. Figures with essential color discrimination
Certain ﬁgures in this article, particularly Figs. 1 and 3–6, are
difﬁcult to interpret in black and white. The full color images can
be found in the on-line version, at http://dx.doi.org/10.1016/j.act-
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